With several drugs in use that inhibit the hepatitis B virus polymerases (nucleos(t)ide analogues (or NUCs)), some argue that new direct-acting antiviral drugs, and new NUCs in particular ...

Single-dose administration of E6F6 could profoundly suppress the levels of hepatitis B surface antigen (HBsAg) and HBV DNA for several weeks in HBV-transgenic mice. E6F6 regimen efficiently prevented ...

In addition to HBsAg, other viral markers such as hepatitis B core-related antigen (HBcrAg) are available, but their potential association with HBV-specific immune responses is not defined yet, which ...

Study: AGA Clinical Practice Guideline on the Prevention and Treatment of Hepatitis B Virus Reactivation ... positive for the HBV surface antigen (HBsAg) or HBV core antibody (anti-HBc).

Hepatitis B (sometimes referred to as hep B) is a liver infection caused by the hepatitis B virus (HBV). It typically causes symptoms like stomach pain, dark urine, fatigue, fever, jaundice (yellowing ...

Patients receiving B cell-depleting agents (E.g., rituximab), chimeric antigen receptor (CAR)-T cell therapies, or cytokine/integrin inhibitors. Patients receiving tyrosine kinase inhibitor (TKI ...

As the number of immunosuppressive drugs has grown, so has the number of patients referred to gastroenterologists with hepatitis B reactivation ... HBs), and HBV total core Ag (anti-HBc).

In this paper, the authors present an interesting strategy to interfere with the HBV life cycle: the preparation of geranyl and peptides' dimers that could impede the correct assembly of hepatitis B ...

Here we investigated the hepatitis B core protein (HBc) that forms the viral capsids and plays a vital role in the HBV life cycle. We explored two distinct binding pockets on the HBV capsid: the ...